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ENGRAFTMENT AND IMMUNOLOGIC RECOVERY IN SIX ADULT PA-
TIENTS TREATED WITH BUCYT AND HUMAN UMBILICAL CORD STEM
CELL TRANSPLANTATION
Janakiraman, N., Nath, R., Chamarthy, U., Vial, I., Fortney, C., Ray,
K. Henry Ford Health System, Detroit, MI.
Between 6/2000 and 6/2003 six adult patients, age 26-58, re-
ceived BuCyT followed by umbilical cord stem cell transplant for
various diagnoses. AML  2, ALL  1, CLL  1, myeloma  1,
and SAA  1. All except one patient received 1 or 2 antigen
mismatched stem cells. They received a median of 2.18 x 10 x 7
TNC/kg (range 1.48-3.12) and CD34  1.5 x 10 x 5/kg (range
0.4-4.2). Median time to ANC 500 was 26 days (range 15-46) and
platelet 20,000 was 66 days (range 42-191). At 1 year, median CD4
count was 357 in 4 patients (range 264-715) and IgG level was 840
mg/dl (range 820-1640). All six patients had 100% donor engraft-
ment documented by STR analysis as early as 1-2 months. Overall
Grade III Acute GVHD was seen in 3 patients (2 skin and 1 gut).
No Grade IV GVHD was seen. Limited chronic GVHD involving
the skin and mucosa was seen in 4 patients. Two patients had
recurrent CMV reactivation and in one of them it contributed to
delayed platelet engraftment. One patient had bacterial meningitis
caused by Flavobacterium Meningo Septicum and 1 patient had
aspergillus sinusitis. With a median followup of 18 months (4-40
months), all 6 patients are alive and in remission/stable disease. In
summary, umbilical cord stem cell transplant is an alternate source
of stem cells for patients without matched sibling donors. Though
the platelet engraftment may be delayed, the transplant related
morbidity is small in this small group of poor risk patients.
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SIGNIFICANT DECREASED LIPOPOLYSACCHARIDE (LPS)-ACTIVATED
CYTOKINE/RECEPTOR, CHEMOKINE, IMMUNOREGULATORY, TRAN-
SCRIPTION, APOPTOTIC, SIGNALING AND CELL STRUCTURE GENE
EXPRESSION IN CORD BLOOD (CB) COMPARED TO ADULT PERIPH-
ERAL BLOOD (APB) MONOCYTES BY OLIGONUCLEOTIDE GENE EX-
PRESSION MICROARRAY: INSIGHT INTO DIFFERENTIAL APB VERSUS
CB MONOCYTE STRUCTURE AND FUNCTION
Jiang, H., van de Ven, C., Satwani, P., Baxi, L., Cairo, M.S. Children’s
Hospital of New York-Presbyterian, Columbia University, New York,
NY.
Umbilical cord blood hematopoiesis and cellular immunity are
developmentally immature when compared with adult peripheral
blood (Cairo et al, Blood 90:4465,1997). We and others have
demonstrated that umbilical cord blood transplantation (UCBT)
is associated with decreased (grade III-IV) aGVHD, but de-
layed immune reconstitution (Abu-Ghosh/Cairo et al, BMT 24:
535,1999). Recently, the contribution of allograft monocytes to the
induction of GVHD and/or immune tolerance has been demon-
strated (Aranha et al, Haematologica, 87:219, 2002). Monocytes
are critically important in the generation of cytokines, chemokines,
immune mediators and the initiation of the cellular immune re-
sponses. We and others have previously demonstrated signiﬁcant
dysregulated cytokine gene expression and protein production and
in vitro functional activities of activated CB versus APB MNC. In
this study we compared, by oligonucleotide microarray, the differ-
ential gene expression proﬁles of basal and LPS-activated APB
versus CB monocytes. Brieﬂy, Mo were puriﬁed from fresh CB or
APB (N  5) and stimulated with LPS (10 g/ml, 18 hours).
mRNA was isolated, reverse transcripted to cDNA, labeled and
hybridized to oligonucleotides (Affymetrix, U95A) (Huang et al,
Science 294:870, 2001). Data was analyzed by Microarray Suite
Version 5.0 (Affymetrix) and hierarchical clustering analysis was
performed by GeneSpring 5.0 software (Silicon Genetics). Quan-
titative real time PCR (LightCycler-RNA ampliﬁcation SYBR
Green I kit, Roche Molecular Biochemicals) was used to examine
selected genes to conﬁrm expression levels. We demonstrated
patterns of signiﬁcant differential ampliﬁed gene expression in
LPS-activated APB versus CB monocytes including cytokine (G-
CSF, 14 fold), chemokine (MIP-1, 5 fold), immunoregulatory
(MHC DRB1, 5 fold), transcription factor (JunB, 4 fold), signal
transduction (STAT4, 5 fold), apoptotic regulation (BAX, 5 fold)
and cell structure (ladinin 1, 6 fold) among others. These results
suggest that some of these differentially expressed genes may in
part be responsible for the differences in the incidence and severity
of aGVHD, immunoreconstitution and/or the ability to cross more
disparate HLA barriers following UCBT. Moreover, these data
provide insight into the molecular basis for differential cellular
function and immune responses between activated CB and APB
monocytes.
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EXAMINING CYTOTOXIC EFFECTS ON THYMIC RECONSTITUTION: A
MODEL
Prockop, S.E., O’Reilly, R.J., Petrie, H.T. Memorial Sloan Kettering
Cancer Center, New York, NY.
A key component of long-term outcome after BMT is successful
reconstitution of the immune system. Effective reconstitution of
antigen-speciﬁc immunity requires de novo T cell generation.
Bone marrow derived progenitors seed the thymus and undergo a
complex process involving lineage commitment, proliferation and
selection. This process requires coordinated interaction of mar-
row-derived lymphoid progenitors with thymic stromal cells. Dis-
ruption of the microenvironment can result in disrupted T cell
lymphopoiesis. One cause of prolonged defects in generating func-
tional T cells after BMT is damage to the thymic microenviron-
ment. However, the impact of individual agents, administered at
myeloablative or non-myeloablative doses, on the thymic micro-
environment has not been fully evaluated. In addition, mechanisms
by which stromal injury modiﬁes T cell production and maturation
have only begun to be understood. We have developed a model
system using immunodeﬁcient mice as a platform on which to
assess thymic reconstitution. The thymus of mice deﬁcient for the
alpha chain of the IL-7 receptor (IL7R
/
) is relatively depleted
of lymphoid cells and can be reconstituted following transplant of
wild type marrow without prior myeloablative or immunosuppres-
sive treatment. Injection of low doses of wild type bone marrow
into these mice results in a normally cellular thymus repopulated
with donor derived lymphocytes. The ability to achieve this recon-
stitution appears to depend on absolute numbers of early intra-
thymic precursors, rather than on total thymic cellularity. Our
model system allows the evaluation of thymic reconstitution after
single agent regimens insufﬁcient to allow donor cell engraftment
in wild type mice. We have exploited it to differentially assess the
effects of cytotoxic agents including radiation and immunosuppres-
sive drugs, on the capacity of the thymic microenvironment to
support the maturation of normal lympoid progenitors. The effects
of several agents on thymic reconstitution will be presented. For
example, after low dose TBI (350rads), reconstitution is preserved,
while after high dose (900rads)TBI it is not. It is anticipated that
this information will lead to strategies to minimize delayed im-
mune reconstitution and to augment T cell lymphopoiesis post-
transplant. In addition, further evaluation of impaired thymic re-
constitution will augment the understanding of lymphostromal
interactions crucial to normal T cell lymphopoiesis.
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IMMUNE RECONSTITUTION AFTER ALLOGENEIC BONE MARROW
TRANSPLANTATION INVOLVES PERIPHERAL T CELL APOPTOSIS
Alpdogan, O.1, McGoldrick, S.1, Budak-Alpdogan, T.2, Hubbard,
V.M.1, Eng, J.M.1, Muriglan, S.J.1, Kochman, A.1, van den Brink,
M.R.M.1 1. Memorial-Sloan Kettering Cancer Center, New York, NY;
2. The Cancer Institute of New Jersey, New Brunswick, NJ.
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Post-transplant T cell deﬁciency (especially in adults) is related to
impaired thymus-dependent lymphopoiesis. However, others and
we have previously found that peripheral T cell apoptosis in recip-
ients of allogeneic bone marrow transplantation (allo BMT) is
increased. We used murine allo BMTmodels to analyze peripheral
T cell apoptosis in three different T cell populations after allo
BMT: T cells derived from (a) donor bone marrow (BM) precur-
sors (de novo generated), (b) infused mature donor T cells in the
allograft (alloreactive and non-alloreactive), and (c) residual host T
cells. In the ﬁrst experiments, we found an increased percentage of
apoptotic (Annexin-V) T cells in both donor derived de novo
generated CD4 and CD8 T cells at day 28 after transplant in
recipients of a T cell depleted (TCD) BMT without GVHD. This
was associated with decreased levels of intracellular Bcl-2 in de
novo generated T cells from both young and old recipients of an
allo TCD BMT. The increased percentages of apoptotic periph-
eral T cells and down regulation of Bcl-2 levels were more prom-
inent in the older recipients. In recipients with GVHD, we found
a severe loss of thymic cellularity, low numbers of BM derived de
novo generated T cells with a high fraction of apoptotic cells and
very low Bcl-2 expression and increased caspase 8 and 9 activation,
Conversely, alloreactive T cells (derived from the infused mature
donor T cells in the allograft) showed upregulation of Fas expres-
sion, higher Bcl-2 levels, less caspase activity and ﬁnally, lower
numbers of apoptotic T cells compared to BM derived T cells. To
determine the effects of Bcl-2 and Fas on T cell reconstitution in
allo BMT recipients, we transplanted donor allografts consisting of
BM from Bcl-2 overexpressing transgenic mice (Bcl-2 Tg) or BM
from Fas-deﬁcient lpr mice with or without wild type congenic T
cells (B6.Ly5.1) into lethally irradiated recipients. Bcl-2 Tg as well
as lpr BM rescued post-transplant thymic cellularity and distribu-
tion and increased CD4 and CD8 T cell numbers in the
periphery, however no change in the fraction of apoptotic cells was
observed. In contrast, post transplant administration of Interleu-
kin-7 and Interleukin-15 reduced the number of apoptotic T cells
in the periphery.
We conclude that peripheral T cell apoptosis is an important
factor in the delay of post transplant T cell reconstitution espe-
cially in older recipients of allo BMT and in recipients with
GVHD.
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IL-15 AS A POTENTIAL REGULATOR OF PERIPHERAL NK AND CD8 T
CELL HOMEOSTASIS
Carson, J.M.1, Villalba, H.1, Boyiadzis, M.1, Memon, S.A.1, Castro,
K.1, Love, C.2, Odom, J.1, Wayne, A.2, Dean, R.1, Fowler, D.1, Bishop,
M.R.1, Gress, R.E.1, Hakim, F.T.1 1. Experimental Transplantation &
Immunology Branch, National Cancer Institute, Bethesda, MD; 2. Pe-
diatrics Branch, Bethesda, MD.
Interleukin-15 (IL-15) has been demonstrated to play a critical
role in the proliferation, differentiation, and survival of natural
killer (NK) and CD8 memory T cell populations. Because NK
and memory CD8 T cells recover rapidly following allogeneic
transplantation, we investigated the role of IL-15 as a potential
homeostatic regulator of these two cell types. 39 patients under-
going allogeneic transplant for hematological and non-hematolog-
ical malignancies were assessed for plasma IL-15 levels by ELISA
and IL-15 receptor expression by ﬂow cytometry. The median
plasma IL-15 level from healthy donors was 0.01 pg/ml (range
0.01-.12 pg/ml). Pretreatment median levels of IL-15 in patient
plasma were 0.85 pg/ml (range 0.01-9.7); median NK levels were
105 cells/microL (range 5-573) and CD8 levels were 327 cells/
microL (range 19-1490). IL-15 levels increased through successive
rounds of cytoreductive chemotherapy. Following a high dose
ﬂudarabine/cytoxan conditioning regimen preceding transplant,
IL-15 levels were on average increased by 100 fold from pretreat-
ment levels to a median of 44 pg/ml (range 25-401) (P  0.0001).
NK and CD8 T cell levels at this point were reduced to a median
level of 0 cells/microL (range 0-23). Concurrent with the rapid
recovery of NK (median 223 cells/microL, range 0-816) and
CD8 (median 252 cells/microL, range 11-897) T cells at 2 weeks,
IL-15 levels in the peripheral blood decreased to median levels of
8.7 pg/ml (range 0.9-160). IL-15 levels continued to fall concur-
rent with recovery of cell populations. Each of the 39 patients,
regardless of patient age (adult or pediatric) or graft composition
(CD34 selected versus T-replete) demonstrated the same spike in
plasma IL-15 levels on the day of transplant. Consistent with a key
role for IL-15, we found that the IL-2/IL-15 receptor beta was
expressed at an elevated level on all NK cells and was increased on
CD8 T cells in the post transplant period, whereas the IL-2
receptor alpha chain was expressed at a low level in these popula-
tions. The rise in IL-15 levels may be due to reduced consumption
by therapy diminished populations of lymphocytes or increased
production in response to inﬂammatory cytokines triggered by the
transplant regimen. In either case, these data support the possibil-
ity that IL-15 serves as a critical homeostatic cytokine post trans-
plant, stimulating the initial rapid generation of NK cells and the
expansion of NK and memory CD8 T cell populations.
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T CELL REPERTOIRE COMPLEXITY IS CONSERVED AFTER L-LEUCYL-
L-LEUCINE METHYL ESTER (LLME) TREATMENT OF DONOR LYMPHO-
CYTE INFUSIONS
Friedman, T.M., Hopely, D.D., Filicko, J.E., Grosso, L., Williams, A.,
Kakhniashvili, I., Korngold, R., Flomenberg, N. Jefferson Medical Col-
lege, Kimmel Cancer Center, Philadelphia, PA.
Delayed and/or incomplete T cell reconstitution following allo-
geneic hematopoietic stem cell transplantation (HSCT) is a major
risk factor for patient mortality. One approach to rectify this
problem is to administer immunocompetent T cells in the form of
delayed donor lymphocyte infusions (DLI). However, the devel-
opment of graft-versus-host disease (GVHD) is a potential com-
plication of this procedure. We previously found in P3 F1 hap-
loidentical murine models that the ex-vivo treatment of donor
lymphocytes with L-leucyl-L-leucine methyl ester (LLME) can
prevent the onset of GVHD after DLI (BBMT 8:303,2002).
LLME is a lysosomotropic agent that preferentially acts upon cells
containing dipeptidyl peptidase I enzymes (DPPI) in their gran-
ules. The overall effect is to induce cell death of most NK cells,
monocytes, granulocytes, the majority of CD8 T cells, and a
fraction of CD4 T cells. Our previous preclinical studies have
formed the basis of an ongoing phase I clinical trial in which
patients received LLME-treated DLI from their original donor in
an attempt to accelerate T cell reconstitution. In order to under-
stand how this treatment strategy might impact upon the complex-
ity of the DLI T cell repertoire, we used TCR V spectratype
analysis to evaluate the DLI product pre and post-LLME treat-
ment. Peripheral blood T cells obtained from the donors at the
time of DLI, prior to LLME treatment, served as the baseline
spectratype for V complexity. The repertoire complexity of each
LLME-treated DLI product was determined by comparison to its
untreated sample. The results of the spectratype analysis indicated
that the LLME-treated DLI product exhibited CDR3-size distri-
bution complexities similar to its untreated donor sample. In ad-
dition, comparisons of the CD4 T cell repertoire from the donor
before LLME treatment to that of the patient post DLI demon-
strated equal complexity for 92% of the resolvable V families.
Lastly, the in vitro proliferative capacity of an LLME-treated
product in response to third party stimulation in a one-way mixed
lymphocyte reaction was comparable to the untreated product.
Since it appears that LLME treatment of DLI does not adversely
impact the complexity of the T cell repertoire or its functional
capacity, this transplant strategy is likely to afford advantages with
regard to mounting responses to opportunistic infections and pre-
venting leukemic relapse.
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REDUCING PRETRANSPLANT CAMPATH-1H DOSE DOES NOT PREVENT
EARLY CMV REACTIVATION POST ALLOGENEIC STEM CELL TRANS-
PLANTATION
Schunn, G.1, Devetten, M.P.2, Craig, M.1, Bunner, P.1, Beall, C.1,
Ericson, S.G.1 1. West Virginia University Hospital, Morgantown, WV;
2. University of Nebraska Medical Center, Omaha, NE.
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